Gilead Phase III Program For Two-Drug HCV Combo On Faster Pace Than Expected
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company also updates Phase II ELECTRON data from November, showing all nine patients in a null-responder cohort achieved sustained virological response after four weeks of therapy with combo.